TWI402074B - 藉由特定多糖類來降低胃灼熱及胃食道逆流疾病（ｇｅｒｄ）之症狀的方法 - Google Patents
藉由特定多糖類來降低胃灼熱及胃食道逆流疾病（ｇｅｒｄ）之症狀的方法 Download PDFInfo
- Publication number
- TWI402074B TWI402074B TW096117078A TW96117078A TWI402074B TW I402074 B TWI402074 B TW I402074B TW 096117078 A TW096117078 A TW 096117078A TW 96117078 A TW96117078 A TW 96117078A TW I402074 B TWI402074 B TW I402074B
- Authority
- TW
- Taiwan
- Prior art keywords
- polysaccharide
- fenugreek
- acid
- viscosity
- galactomannose
- Prior art date
Links
- 229920001282 polysaccharide Polymers 0.000 title claims abstract description 45
- 239000005017 polysaccharide Substances 0.000 title claims abstract description 45
- 208000021302 gastroesophageal reflux disease Diseases 0.000 title claims abstract description 24
- 201000006549 dyspepsia Diseases 0.000 title claims abstract description 18
- 208000024798 heartburn Diseases 0.000 title claims abstract description 17
- 150000004676 glycans Chemical class 0.000 title claims abstract description 13
- 208000024891 symptom Diseases 0.000 title claims abstract description 9
- 238000000034 method Methods 0.000 title description 8
- 230000036571 hydration Effects 0.000 claims abstract description 14
- 238000006703 hydration reaction Methods 0.000 claims abstract description 14
- 238000002360 preparation method Methods 0.000 claims abstract description 12
- 239000000825 pharmaceutical preparation Substances 0.000 claims abstract description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 21
- 239000000203 mixture Substances 0.000 claims description 16
- 244000250129 Trigonella foenum graecum Species 0.000 claims description 14
- 235000001484 Trigonella foenum graecum Nutrition 0.000 claims description 14
- 235000001019 trigonella foenum-graecum Nutrition 0.000 claims description 14
- 239000000243 solution Substances 0.000 claims description 12
- 238000011282 treatment Methods 0.000 claims description 12
- 239000003814 drug Substances 0.000 claims description 10
- 210000003238 esophagus Anatomy 0.000 claims description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 7
- 210000001156 gastric mucosa Anatomy 0.000 claims description 7
- 235000012054 meals Nutrition 0.000 claims description 7
- 208000035475 disorder Diseases 0.000 claims description 6
- 239000007788 liquid Substances 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 6
- 238000000576 coating method Methods 0.000 claims description 5
- -1 flavorings Substances 0.000 claims description 5
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 5
- 239000007864 aqueous solution Substances 0.000 claims description 4
- 239000002775 capsule Substances 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- 230000006378 damage Effects 0.000 claims description 4
- 239000007937 lozenge Substances 0.000 claims description 4
- 238000006467 substitution reaction Methods 0.000 claims description 4
- 238000011161 development Methods 0.000 claims description 3
- 238000005259 measurement Methods 0.000 claims description 3
- 239000006187 pill Substances 0.000 claims description 3
- 239000003755 preservative agent Substances 0.000 claims description 3
- 239000002562 thickening agent Substances 0.000 claims description 3
- OMDQUFIYNPYJFM-XKDAHURESA-N (2r,3r,4s,5r,6s)-2-(hydroxymethyl)-6-[[(2r,3s,4r,5s,6r)-4,5,6-trihydroxy-3-[(2s,3s,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]methoxy]oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O[C@H]2[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)[C@H](O)[C@H](O)[C@H](O)O1 OMDQUFIYNPYJFM-XKDAHURESA-N 0.000 claims description 2
- 229920000926 Galactomannan Polymers 0.000 claims description 2
- 208000027418 Wounds and injury Diseases 0.000 claims description 2
- 239000003963 antioxidant agent Substances 0.000 claims description 2
- 239000003086 colorant Substances 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- 210000000981 epithelium Anatomy 0.000 claims description 2
- 239000000945 filler Substances 0.000 claims description 2
- 235000003599 food sweetener Nutrition 0.000 claims description 2
- 239000003979 granulating agent Substances 0.000 claims description 2
- 208000014674 injury Diseases 0.000 claims description 2
- 230000035935 pregnancy Effects 0.000 claims description 2
- 239000003765 sweetening agent Substances 0.000 claims description 2
- 230000001934 delay Effects 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 239000000314 lubricant Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 230000001052 transient effect Effects 0.000 claims 1
- 150000004804 polysaccharides Polymers 0.000 description 36
- 239000000835 fiber Substances 0.000 description 19
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 18
- 210000002784 stomach Anatomy 0.000 description 17
- 235000013305 food Nutrition 0.000 description 15
- 230000028327 secretion Effects 0.000 description 14
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 12
- 239000002253 acid Substances 0.000 description 11
- 210000004027 cell Anatomy 0.000 description 10
- 239000008194 pharmaceutical composition Substances 0.000 description 9
- 102400000921 Gastrin Human genes 0.000 description 8
- 108010052343 Gastrins Proteins 0.000 description 8
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 8
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 8
- AOXOCDRNSPFDPE-UKEONUMOSA-N chembl413654 Chemical compound C([C@H](C(=O)NCC(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](C)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)CNC(=O)[C@@H](N)CCC(O)=O)C1=CC=C(O)C=C1 AOXOCDRNSPFDPE-UKEONUMOSA-N 0.000 description 8
- 235000010443 alginic acid Nutrition 0.000 description 7
- 229920000615 alginic acid Polymers 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 6
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 6
- 230000002496 gastric effect Effects 0.000 description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- 210000004877 mucosa Anatomy 0.000 description 6
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 5
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 5
- 108010047320 Pepsinogen A Proteins 0.000 description 5
- 230000002378 acidificating effect Effects 0.000 description 5
- 229940072056 alginate Drugs 0.000 description 5
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 5
- 239000002552 dosage form Substances 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 229930182830 galactose Natural products 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- AEMOLEFTQBMNLQ-VANFPWTGSA-N D-mannopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@@H]1O AEMOLEFTQBMNLQ-VANFPWTGSA-N 0.000 description 4
- IAJILQKETJEXLJ-RSJOWCBRSA-N aldehydo-D-galacturonic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-RSJOWCBRSA-N 0.000 description 4
- IAJILQKETJEXLJ-QTBDOELSSA-N aldehydo-D-glucuronic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-QTBDOELSSA-N 0.000 description 4
- 229940069428 antacid Drugs 0.000 description 4
- 239000003159 antacid agent Substances 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 210000004211 gastric acid Anatomy 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- 229940097043 glucuronic acid Drugs 0.000 description 4
- 229960001340 histamine Drugs 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 229940126409 proton pump inhibitor Drugs 0.000 description 4
- 239000000612 proton pump inhibitor Substances 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 3
- 241000219122 Cucurbita Species 0.000 description 3
- 235000009852 Cucurbita pepo Nutrition 0.000 description 3
- 244000303965 Cyamopsis psoralioides Species 0.000 description 3
- 208000007882 Gastritis Diseases 0.000 description 3
- 229920002907 Guar gum Polymers 0.000 description 3
- 208000025865 Ulcer Diseases 0.000 description 3
- 206010047700 Vomiting Diseases 0.000 description 3
- 230000004888 barrier function Effects 0.000 description 3
- 239000011248 coating agent Substances 0.000 description 3
- 210000001198 duodenum Anatomy 0.000 description 3
- 210000003736 gastrointestinal content Anatomy 0.000 description 3
- 235000010417 guar gum Nutrition 0.000 description 3
- 239000003485 histamine H2 receptor antagonist Substances 0.000 description 3
- 210000000111 lower esophageal sphincter Anatomy 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 3
- 229940111202 pepsin Drugs 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 210000000813 small intestine Anatomy 0.000 description 3
- 231100000397 ulcer Toxicity 0.000 description 3
- 230000008673 vomiting Effects 0.000 description 3
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 2
- 240000008886 Ceratonia siliqua Species 0.000 description 2
- 235000013912 Ceratonia siliqua Nutrition 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 208000034991 Hiatal Hernia Diseases 0.000 description 2
- 206010020028 Hiatus hernia Diseases 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 102000005157 Somatostatin Human genes 0.000 description 2
- 108010056088 Somatostatin Proteins 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 229920001615 Tragacanth Polymers 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 239000000783 alginic acid Substances 0.000 description 2
- 229960001126 alginic acid Drugs 0.000 description 2
- 150000004781 alginic acids Chemical class 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 235000013361 beverage Nutrition 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 235000010418 carrageenan Nutrition 0.000 description 2
- 239000000679 carrageenan Substances 0.000 description 2
- 229920001525 carrageenan Polymers 0.000 description 2
- 229940113118 carrageenan Drugs 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 210000004913 chyme Anatomy 0.000 description 2
- 239000000306 component Substances 0.000 description 2
- 230000008602 contraction Effects 0.000 description 2
- 230000002354 daily effect Effects 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 210000004188 enterochromaffin-like cell Anatomy 0.000 description 2
- 208000028299 esophageal disease Diseases 0.000 description 2
- 235000013350 formula milk Nutrition 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000027119 gastric acid secretion Effects 0.000 description 2
- 230000030136 gastric emptying Effects 0.000 description 2
- 210000004051 gastric juice Anatomy 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000000665 guar gum Substances 0.000 description 2
- 229960002154 guar gum Drugs 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 230000007794 irritation Effects 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000010410 layer Substances 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- 210000003097 mucus Anatomy 0.000 description 2
- 210000001087 myotubule Anatomy 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 210000001711 oxyntic cell Anatomy 0.000 description 2
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 230000003449 preventive effect Effects 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 150000003180 prostaglandins Chemical class 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 230000022676 rumination Effects 0.000 description 2
- 208000015212 rumination disease Diseases 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 description 2
- 229960000553 somatostatin Drugs 0.000 description 2
- 210000005070 sphincter Anatomy 0.000 description 2
- 235000021259 spicy food Nutrition 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 210000001186 vagus nerve Anatomy 0.000 description 2
- 229920001285 xanthan gum Polymers 0.000 description 2
- 235000010493 xanthan gum Nutrition 0.000 description 2
- 239000000230 xanthan gum Substances 0.000 description 2
- 229940082509 xanthan gum Drugs 0.000 description 2
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- PVKZAQYUEVYDGV-CGOOJBRSSA-N (2r,3s,4r,5r)-3,4,5,6-tetrahydroxy-2-[(3r,4s,5r)-3,4,5-trihydroxyoxan-2-yl]oxyhexanal Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](C=O)OC1OC[C@@H](O)[C@H](O)[C@H]1O PVKZAQYUEVYDGV-CGOOJBRSSA-N 0.000 description 1
- LUEWUZLMQUOBSB-FSKGGBMCSA-N (2s,3s,4s,5s,6r)-2-[(2r,3s,4r,5r,6s)-6-[(2r,3s,4r,5s,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5s,6r)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-4,5-dihydroxy-2-(hydroxymethyl)oxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@@H](O[C@@H]2[C@H](O[C@@H](OC3[C@H](O[C@@H](O)[C@@H](O)[C@H]3O)CO)[C@@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O LUEWUZLMQUOBSB-FSKGGBMCSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 229920002749 Bacterial cellulose Polymers 0.000 description 1
- 206010006784 Burning sensation Diseases 0.000 description 1
- 235000017399 Caesalpinia tinctoria Nutrition 0.000 description 1
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 239000001879 Curdlan Substances 0.000 description 1
- 229920002558 Curdlan Polymers 0.000 description 1
- 235000008222 Cyamopsis psoralioides Nutrition 0.000 description 1
- AEMOLEFTQBMNLQ-BZINKQHNSA-N D-Guluronic Acid Chemical compound OC1O[C@H](C(O)=O)[C@H](O)[C@@H](O)[C@H]1O AEMOLEFTQBMNLQ-BZINKQHNSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- 229920002148 Gellan gum Polymers 0.000 description 1
- 229920002581 Glucomannan Polymers 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 206010061297 Mucosal erosion Diseases 0.000 description 1
- 206010028116 Mucosal inflammation Diseases 0.000 description 1
- 206010028124 Mucosal ulceration Diseases 0.000 description 1
- 208000014174 Oesophageal disease Diseases 0.000 description 1
- 206010030201 Oesophageal ulcer Diseases 0.000 description 1
- 206010030216 Oesophagitis Diseases 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 208000008469 Peptic Ulcer Diseases 0.000 description 1
- 239000004264 Petrolatum Substances 0.000 description 1
- 244000046052 Phaseolus vulgaris Species 0.000 description 1
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 1
- 102100021904 Potassium-transporting ATPase alpha chain 1 Human genes 0.000 description 1
- 108010083204 Proton Pumps Proteins 0.000 description 1
- 241000282849 Ruminantia Species 0.000 description 1
- 229910004298 SiO 2 Inorganic materials 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- 241000388430 Tara Species 0.000 description 1
- 201000008629 Zollinger-Ellison syndrome Diseases 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 230000009858 acid secretion Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000001458 anti-acid effect Effects 0.000 description 1
- 229940006138 antiglaucoma drug and miotics prostaglandin analogues Drugs 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000000305 astragalus gummifer gum Substances 0.000 description 1
- 239000005016 bacterial cellulose Substances 0.000 description 1
- AEMOLEFTQBMNLQ-UHFFFAOYSA-N beta-D-galactopyranuronic acid Natural products OC1OC(C(O)=O)C(O)C(O)C1O AEMOLEFTQBMNLQ-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 235000021152 breakfast Nutrition 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000010924 continuous production Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 235000019316 curdlan Nutrition 0.000 description 1
- 229940078035 curdlan Drugs 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000008260 defense mechanism Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000013325 dietary fiber Nutrition 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- UGMCXQCYOVCMTB-UHFFFAOYSA-K dihydroxy(stearato)aluminium Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[Al](O)O UGMCXQCYOVCMTB-UHFFFAOYSA-K 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 230000002183 duodenal effect Effects 0.000 description 1
- 208000000718 duodenal ulcer Diseases 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 208000019064 esophageal ulcer Diseases 0.000 description 1
- 208000006881 esophagitis Diseases 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000008713 feedback mechanism Effects 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 239000005428 food component Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 201000000052 gastrinoma Diseases 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 235000010492 gellan gum Nutrition 0.000 description 1
- 239000000216 gellan gum Substances 0.000 description 1
- 229940046240 glucomannan Drugs 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- IXCSERBJSXMMFS-UHFFFAOYSA-N hcl hcl Chemical compound Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 208000021822 hypotensive Diseases 0.000 description 1
- 230000001077 hypotensive effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 230000000622 irritating effect Effects 0.000 description 1
- 235000021374 legumes Nutrition 0.000 description 1
- 235000005955 light diet Nutrition 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000008297 liquid dosage form Substances 0.000 description 1
- 239000010687 lubricating oil Substances 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000013160 medical therapy Methods 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000003232 mucoadhesive effect Effects 0.000 description 1
- 230000004682 mucosal barrier function Effects 0.000 description 1
- 230000008881 mucosal defense Effects 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 231100000017 mucous membrane irritation Toxicity 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 235000021590 normal diet Nutrition 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 230000003076 paracrine Effects 0.000 description 1
- 230000001991 pathophysiological effect Effects 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 208000011906 peptic ulcer disease Diseases 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000008855 peristalsis Effects 0.000 description 1
- 229940066842 petrolatum Drugs 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 229960003742 phenol Drugs 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 239000011241 protective layer Substances 0.000 description 1
- 230000009979 protective mechanism Effects 0.000 description 1
- 230000013777 protein digestion Effects 0.000 description 1
- 210000001187 pylorus Anatomy 0.000 description 1
- 235000018770 reduced food intake Nutrition 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 230000017619 regulation of gastric acid secretion Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 230000036186 satiety Effects 0.000 description 1
- 235000019627 satiety Nutrition 0.000 description 1
- 208000011818 severe chest pain Diseases 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 235000017550 sodium carbonate Nutrition 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 235000011008 sodium phosphates Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000007892 solid unit dosage form Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 210000002325 somatostatin-secreting cell Anatomy 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 210000004876 tela submucosa Anatomy 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 210000001578 tight junction Anatomy 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical class [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 230000036269 ulceration Effects 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/718—Starch or degraded starch, e.g. amylose, amylopectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/722—Chitin, chitosan
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/724—Cyclodextrins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/731—Carrageenans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/732—Pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/736—Glucomannans or galactomannans, e.g. locust bean gum, guar gum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/738—Cross-linked polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Medicines Containing Plant Substances (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP06076056A EP1859786A1 (en) | 2006-05-16 | 2006-05-16 | A method to reduce the symptoms of heartburn and gastro-oesophageal reflux disease (GERD) by specific polysaccharides |
| US80631306P | 2006-06-30 | 2006-06-30 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| TW200812596A TW200812596A (en) | 2008-03-16 |
| TWI402074B true TWI402074B (zh) | 2013-07-21 |
Family
ID=37806824
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW096117078A TWI402074B (zh) | 2006-05-16 | 2007-05-14 | 藉由特定多糖類來降低胃灼熱及胃食道逆流疾病（ｇｅｒｄ）之症狀的方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US20090252792A1 (https=) |
| EP (2) | EP1859786A1 (https=) |
| JP (1) | JP2009537512A (https=) |
| KR (1) | KR20090048393A (https=) |
| AT (1) | ATE514415T1 (https=) |
| AU (1) | AU2007250624B2 (https=) |
| RU (1) | RU2432167C2 (https=) |
| TW (1) | TWI402074B (https=) |
| WO (1) | WO2007133082A1 (https=) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090148530A1 (en) * | 2007-12-08 | 2009-06-11 | Jamie Koufman | Method for prevention and treatment of reflux injury in the aerodigestive tract and laryngopharynx caused by pepsin |
| EP2346351B1 (en) | 2008-09-22 | 2019-07-03 | Rubicon Research Private Limited | Compositions exhibiting delayed transit through the gastrointestinal tract |
| DK2564840T3 (en) | 2010-04-26 | 2015-03-02 | De Santos Angel Manuel Gago | Compositions for symptomatic relief of abdominal pain or gastroesophageal reflux |
| ITRM20120041A1 (it) * | 2012-02-08 | 2013-08-09 | Dicofarm Spa | "prodotto a base di glucomannano e chitosano utile per il trattamento del reflusso gastroesofageo" |
| ITRM20120084A1 (it) * | 2012-03-07 | 2013-09-08 | Aboca Spa Societa Agricola | Miscela prebiotica. |
| EP2827839B1 (en) | 2012-03-20 | 2019-02-27 | Particle Dynamics International, LLC | Gelling agent-based dosage form |
| ITMI20130960A1 (it) * | 2013-06-11 | 2014-12-12 | Novintethical Pharma Sagl | Composizioni a base di xiloglucano per il trattamento di disturbi gastrointestinali |
| IT201700091733A1 (it) * | 2017-08-08 | 2019-02-08 | Neilos S R L | Composizione per somministrazione orale per uso nel trattamento terapeutico o preventivo dei disturbi o malattia da reflusso gastroesofageo |
| JP2019064980A (ja) * | 2017-10-03 | 2019-04-25 | 小林製薬株式会社 | 逆流性食道炎改善剤 |
| AU2019312160B2 (en) | 2018-07-23 | 2024-02-22 | Nutragenom, Llc | Composition and methods for generating and sustaining molecular hydrogen (H2) in aqueous systems |
| CN111227156A (zh) * | 2020-01-20 | 2020-06-05 | 陕西科技大学 | 一种抑制反酸的固体饮料及其制备方法 |
| WO2022240224A1 (ko) * | 2021-05-14 | 2022-11-17 | 한국식품연구원 | 젤란검을 유효성분으로 하는 장내 균총 개선용 조성물 및 이를 포함하는 대사성 질환 개선, 예방 또는 치료용 조성물 |
| TWI777673B (zh) * | 2021-07-16 | 2022-09-11 | 陳昭誠 | 由β-1-4-葡聚醣形成之纖維於製備用於治療或預防胃食道逆流之組成物之用途 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2349570A (en) * | 1999-05-05 | 2000-11-08 | Reckitt & Colmann Prod Ltd | Compositions for treatment of disorders of the oesophagus |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3152319C2 (de) * | 1980-09-03 | 1986-05-07 | Kyosei Pharmaceutical Co., Ltd., Hokkaido | Verwendung einer Lösung eines Salzes der Alginsäure zur Behandlung von Strahlenschäden und Ulcera |
| IL108583A (en) * | 1994-02-07 | 1997-06-10 | Yissum Res Dev Co | Galactomannan emulsions and comestible products containing the same |
| GB9708773D0 (en) * | 1997-04-30 | 1997-06-25 | Reckitt & Colmann Prod Ltd | Organic compositions |
| CA2206157C (en) * | 1997-05-26 | 2000-06-13 | Cheng, Peter | Method of extraction of commercially valuable fractions of fenugreek |
| GB0005743D0 (en) * | 2000-03-10 | 2000-05-03 | Reckitt & Colmann Prod Ltd | Pharmaceutical compositions including alginates |
| GB2384986B (en) * | 2002-02-12 | 2004-01-07 | Reckitt Benckiser Healthcare | Compositions for the treatment of disorders of the upper gastrointestinal tract |
| CN1780880B (zh) * | 2003-04-25 | 2010-04-28 | 雷克特本克斯尔保健(英国)有限公司 | 可增稠的组合物 |
| ATE390142T1 (de) * | 2003-05-14 | 2008-04-15 | Indus Biotech Pvt Ltd | Synergistische zusammensetzung zur behandlung von diabetes mellitus |
-
2006
- 2006-05-16 EP EP06076056A patent/EP1859786A1/en not_active Withdrawn
-
2007
- 2007-05-14 TW TW096117078A patent/TWI402074B/zh not_active IP Right Cessation
- 2007-05-16 AU AU2007250624A patent/AU2007250624B2/en not_active Ceased
- 2007-05-16 KR KR1020087030557A patent/KR20090048393A/ko not_active Ceased
- 2007-05-16 AT AT07747448T patent/ATE514415T1/de not_active IP Right Cessation
- 2007-05-16 RU RU2008149527/15A patent/RU2432167C2/ru active
- 2007-05-16 JP JP2009510906A patent/JP2009537512A/ja active Pending
- 2007-05-16 US US12/300,632 patent/US20090252792A1/en not_active Abandoned
- 2007-05-16 EP EP07747448A patent/EP2026763B1/en active Active
- 2007-05-16 WO PCT/NL2007/050224 patent/WO2007133082A1/en not_active Ceased
-
2012
- 2012-03-15 US US13/421,741 patent/US20120231078A1/en not_active Abandoned
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2349570A (en) * | 1999-05-05 | 2000-11-08 | Reckitt & Colmann Prod Ltd | Compositions for treatment of disorders of the oesophagus |
Also Published As
| Publication number | Publication date |
|---|---|
| RU2008149527A (ru) | 2010-06-27 |
| KR20090048393A (ko) | 2009-05-13 |
| US20090252792A1 (en) | 2009-10-08 |
| EP2026763A1 (en) | 2009-02-25 |
| JP2009537512A (ja) | 2009-10-29 |
| AU2007250624B2 (en) | 2012-09-20 |
| WO2007133082A1 (en) | 2007-11-22 |
| US20120231078A1 (en) | 2012-09-13 |
| TW200812596A (en) | 2008-03-16 |
| RU2432167C2 (ru) | 2011-10-27 |
| EP1859786A1 (en) | 2007-11-28 |
| AU2007250624A1 (en) | 2007-11-22 |
| ATE514415T1 (de) | 2011-07-15 |
| EP2026763B1 (en) | 2011-06-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI402074B (zh) | 藉由特定多糖類來降低胃灼熱及胃食道逆流疾病（ｇｅｒｄ）之症狀的方法 | |
| US5989588A (en) | Methods and compositions for preventing and treating heartburn | |
| US5854267A (en) | Method for preventing heartburn | |
| US20070202058A1 (en) | Compositions for treating gastric reflux | |
| US12036235B2 (en) | Composition in solid form for use in the treatment of extraoesophageal symptoms of gastric reflux | |
| WO2019087100A1 (en) | Suckable and/or melt-in-mouth tablet based on hyaluronic acid and chondroitin sulphate and salts thereof for use in the treatment of a subpopulation of gerd patients | |
| CN102844077A (zh) | 一种用于中和胃酸的固体药物组合物 | |
| EP2812009B1 (en) | Product comprising glucomannan and chitosan for the treatment of gastroesophageal reflux disease | |
| US20070203242A1 (en) | Method for treating gastric reflux | |
| EP4059506A1 (en) | Composition for the treatment of reflux esophagitis and related symptoms | |
| US11723939B2 (en) | Composition for gastric and oesophageal diseases | |
| AU728423B2 (en) | Methods and compositions for preventing and treating heartburn | |
| WO2010108494A1 (en) | Dayspepsia treatment with alginate | |
| JP2006508083A (ja) | 胃食道逆流症の治療のためのテナトプラゾールの使用 | |
| Brand et al. | Taking the'sauer'out of sauerkraut: a rapid update on the pathophysiology and treatment of gastro-oesophageal reflux disease | |
| CA2178277C (en) | Method for preventing heartburn | |
| PT1019066E (pt) | Métodos e composições para a prevenção e tratamento da azia | |
| BRPI0621391A2 (pt) | combinação sinérgica de inibidores de receptores h2, silicone inerte e um complexo de aluminato de hidroximagnésio | |
| WO2019030629A1 (en) | COMPOSITION FOR ORAL ADMINISTRATION IN THERAPEUTIC OR PREVENTIVE TREATMENT OF DISORDERS OR DISEASE OF GASTROESOPHAGEAL REFLUX | |
| CN102232950A (zh) | 雷贝拉唑在制药中的新的应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | Annulment or lapse of patent due to non-payment of fees |